SEC Form 3 · accession 0001209191-18-021993
Cogent Biosciences, Inc. · COGT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles Wilson
Officer — Chief Executive Officer · Director
Period of report
Mar 28, 2018
Accepted (ET)
Mar 28, 2018 · 8:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001622229
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 5,095,114 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $12.00 | holding | — | — | — | — | Mar 16, 2028 | Common Stock | 213,357 | — | D |
Explanation of responses
- F125% of the shares vest on March 28, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.
Remarks
Exhibit 24 - Power of Attorney (attached)